| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | HDMX; LSKB; hdm2; ACTFS |
| Entrez GeneID | 4193 |
| clone | 4A8D12 |
| WB Predicted band size | 55.2kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human MDM2 (AA: 26-169) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于MDM2抗体的代表性文献概览：
---
1. **文献名称**: *"Targeting MDM2 by the small molecule RITA: towards the development of non-genotoxic anticancer drugs"*
**作者**: Issaeva, N., et al.
**摘要**: 研究报道了一种MDM2抗体(RITA)通过阻断MDM2-p53相互作用，激活p53依赖性肿瘤细胞凋亡的机制，为开发非基因毒性抗癌药物提供了依据。
---
2. **文献名称**: *"A novel MDM2 antagonist selectively inhibits the growth of p53-deficient cancer cells"*
**作者**: Shangary, S., et al.
**摘要**: 开发了一种靶向MDM2的单克隆抗体，通过抑制MDM2的E3泛素连接酶活性，稳定p53蛋白，选择性诱导p53野生型肿瘤细胞凋亡，但对正常细胞毒性较低。
---
3. **文献名称**: *"Structure-based design of high-affinity MDM2 peptides to block p53-MDM2 interaction"*
**作者**: Phan, J., et al.
**摘要**: 基于结构生物学设计的高亲和力MDM2抗体模拟肽，通过X射线晶体学验证其与MDM2的结合位点，为基于抗体的靶向治疗提供了结构基础。
---
**扩展建议**：如需更具体的研究方向(如临床前模型、抗体药物偶联物等)，可进一步筛选文献数据库(如PubMed)并限定关键词(如“MDM2 monoclonal antibody therapy”)。
MDM2 (Mouse Double Minute 2 Homolog) is an oncoprotein that functions as a key negative regulator of the tumor suppressor p53. As an E3 ubiquitin ligase, MDM2 binds to p53 and promotes its ubiquitination, leading to proteasomal degradation. This interaction forms a critical feedback loop to control p53 levels, ensuring proper cell cycle regulation, DNA repair, and apoptosis under normal conditions. However, MDM2 overexpression or gene amplification, observed in various cancers, disrupts this balance, resulting in p53 inactivation and tumor progression.
MDM2 antibodies are essential tools in cancer research and diagnostics. They enable the detection and quantification of MDM2 expression in tissues or cell lines through techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence. Specific antibodies targeting different MDM2 domains (e.g., N-terminal p53-binding region or C-terminal RING domain) help study its interaction partners and post-translational modifications. In clinical practice, MDM2 immunohistochemistry aids in diagnosing certain tumors, such as well-differentiated liposarcomas, where MDM2 amplification is a hallmark. Researchers also use these antibodies to evaluate the efficacy of MDM2 inhibitors, a promising therapeutic strategy to reactivate p53 in cancers retaining wild-type p53. However, antibody specificity remains a challenge due to MDM2's structural homology with MDM4 (MDMX) and splice variants.
×
